My Thesis On $WVE. RA Capital bought $54M after a 50% crash in this Ozempic Competitor.

**$WVE:** Wave Life Sciences

*This is a clinical stage biotech company developing RNA-based medicines.*

They developed an obesity drug (WVE-007) that showed fat loss comparable to GLP-1s like Ozempic but with *once or twice a year dosing* ***without any muscle loss.***

**Why did $WVE crash?**

*Stock dropped* ***50%*** *in a single session* on March 26.

They just had a **"miss"**

WVE-007 at a ***higher dosage*** showed just **0.9%** weight loss over placebo. FDA wants to see **5%** at least.

***RA Capital started buying $54 million on that exact same day.***

Four consecutive days accumulating. ***$30M, then $2.2M, then $16M, then $6.3M.***

**My Thesis:**

RA Capital is one of the most respected specialist healthcare funds in the industry. *They read clinical data for a living.*

***The lower 240mg dose actually worked.*** 14% visceral fat reduction at six months, with patients gaining lean muscle. That's a profile no GLP-1 can match at the moment.

***Ozempic melts fat but it also melts muscle.*** WVE-007 appears to do one without the other.

*Consensus price target* ***$28*** *vs* ***$7.28*** *current price*

The "miss" had some issues.

\--> the trial enrolled people with BMIs around **32**. That's barely obese.

\--> The Phase 2a starting next quarter recruits patients with BMIs of 35 to 50 with actual obesity-related conditions. More fat to lose, better numbers to show.

***Disclaimer: Not Financial Advice. Please Do your own Due Diligence.***

**Date Posted:** *Friday, April 3rd 2:57 PM EST. $WVE Price: $*7.28